Assessing Expression of PD-L1 in Tumor-Associated Macrophages—Reply

In Reply We would like to thank Zhang et al for their interest in our recent phase 1 nonrandomized controlled trial of chemoradiotherapy with concurrent pembrolizumab for the treatment of locally advanced non–small cell lung cancer (NSCLC)¹ and are appreciative of their thoughtful inquiries regarding this work. We would like to address their points in order, as follows.